Profile data is unavailable for this security.
About the company
Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement and complex wounds. Its subsidiaries are Aroa Biosurgery Incorporated and Mesynthes Nominee Limited.
- Revenue in AUD (TTM)59.93m
- Net income in AUD-7.54m
- Incorporated2007
- Employees261.00
- LocationAroa Biosurgery Ltd64 Richard Pearse Drive, MangereAUCKLAND 2022New ZealandNZL
- Phone+64 98693035
- Websitehttps://aroa.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imricor Medical Systems Inc | 931.55k | -34.24m | 99.25m | -- | -- | -- | -- | 106.54 | -0.2175 | -0.2175 | 0.006 | -0.0784 | 0.0559 | 0.8749 | 2.38 | -- | -205.60 | -93.47 | -294.49 | -106.30 | -181.27 | -134.71 | -3,675.60 | -2,462.89 | 0.4944 | -3.64 | 15.92 | -- | -24.56 | -9.29 | -30.36 | -- | -10.82 | -- |
| SDI Ltd | 109.61m | 8.04m | 101.04m | 300.00 | 12.57 | 1.13 | 8.18 | 0.9218 | 0.0676 | 0.0676 | 0.9221 | 0.7494 | 0.8449 | 1.69 | 6.22 | -- | 6.20 | 7.27 | 7.46 | 8.40 | 59.28 | 59.79 | 7.34 | 8.07 | 1.26 | 10.37 | 0.2318 | 51.85 | 13.35 | 7.67 | -3.09 | 4.50 | 52.58 | 5.39 |
| Genetic Signatures Ltd | 16.49m | -18.04m | 139.86m | -- | -- | 3.45 | -- | 8.48 | -0.1245 | -0.1245 | 0.1136 | 0.2172 | 0.3366 | 1.06 | 5.25 | -- | -36.81 | -7.14 | -40.19 | -7.82 | 40.66 | 57.68 | -109.38 | -13.74 | 5.95 | -18,040.00 | 0.0003 | -- | -38.11 | 33.44 | -558.77 | -- | 73.20 | -- |
| Cyclopharm Limited | 32.21m | -4.70m | 162.95m | 87.00 | -- | 5.05 | -- | 5.06 | -0.0508 | -0.0508 | 0.3476 | 0.3428 | 0.6748 | 1.11 | 4.13 | 370,173.10 | -9.85 | -12.60 | -11.92 | -14.94 | 68.15 | 70.20 | -14.60 | -25.47 | 2.32 | -18.40 | 0.1159 | -- | 11.22 | 15.50 | 28.90 | -- | -7.83 | -- |
| ImpediMed Ltd | 10.47m | -19.42m | 163.87m | 76.00 | -- | 3.21 | -- | 15.65 | -0.0102 | -0.0102 | 0.0055 | 0.0252 | 0.1961 | 1.32 | 4.41 | 137,802.60 | -36.37 | -52.27 | -40.94 | -62.34 | 86.95 | 80.64 | -185.47 | -264.76 | 6.85 | -- | 0.0244 | -- | 7.36 | 27.87 | -3.26 | -- | 37.83 | -- |
| Mach7 Technologies Ltd | 26.97m | -5.55m | 166.46m | 90.00 | -- | 3.06 | 76.91 | 6.17 | -0.0231 | -0.0231 | 0.1123 | 0.2256 | 0.3605 | -- | 3.21 | -- | -7.42 | -7.48 | -8.73 | -8.65 | 95.09 | 93.72 | -20.59 | -20.56 | -- | -2,605.17 | 0.0193 | -- | 10.97 | 28.30 | 74.85 | -- | 29.28 | -- |
| EMvision Medical Devices Ltd | 8.86m | -3.22m | 170.85m | -- | -- | 27.30 | -- | 19.28 | -0.0449 | -0.0449 | 0.1186 | 0.0733 | 0.7954 | -- | -- | -- | -28.95 | -67.20 | -45.25 | -79.38 | -- | -- | -36.40 | -175.99 | -- | -35.20 | 0.3424 | -- | 62.08 | 70.47 | 36.64 | -- | -- | -- |
| Aroa Biosurgery Ltd | 59.93m | -7.54m | 185.87m | 261.00 | -- | 2.10 | -- | 3.10 | -0.022 | -0.022 | 0.1746 | 0.2572 | 0.5764 | 1.69 | 3.18 | 229,621.00 | -7.25 | -9.60 | -7.88 | -12.08 | 84.47 | 77.32 | -12.58 | -18.98 | 7.09 | -12.52 | 0.065 | -- | 59.68 | 41.68 | 95.28 | -- | 35.28 | -- |
| Paragon Care Ltd. | 317.39m | 10.31m | 210.38m | 0.00 | 20.63 | 0.838 | 9.53 | 0.6629 | 0.0153 | 0.0124 | 0.4698 | 0.3759 | 0.6806 | 3.00 | 8.84 | -- | 2.54 | -1.78 | 3.32 | -2.33 | 40.92 | 39.55 | 3.73 | -2.58 | 0.7121 | 3.04 | 0.374 | -- | 29.55 | 21.27 | 111.05 | -1.54 | 26.29 | -17.29 |
| 4DMedical Ltd | 1.03m | -30.83m | 225.05m | -- | -- | 2.47 | -- | 219.51 | -0.0882 | -0.0882 | 0.0029 | 0.2332 | 0.0098 | 0.092 | 0.1585 | -- | -29.47 | -43.96 | -39.07 | -57.58 | 95.00 | 32.30 | -3,007.64 | -2,704.36 | 1.79 | -- | 0.0476 | -- | -31.84 | -1.86 | -27.92 | -- | 2.46 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Harbour Asset Management Ltd.as of 30 Apr 2024 | 22.69m | 6.60% |
| Wilson Asset Management (International) Pty Ltd.as of 30 Jun 2023 | 16.06m | 4.67% |
| Guardians of New Zealand Superannuationas of 30 Jun 2023 | 5.39m | 1.57% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.41m | 0.99% |
| DFA Australia Ltd.as of 31 Mar 2024 | 1.31m | 0.38% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 370.19k | 0.11% |
| FCA Corp.as of 31 Mar 2024 | 145.00k | 0.04% |
| Dimensional Fund Advisors Ltd.as of 04 Apr 2024 | 51.76k | 0.02% |
| Acadian Asset Management LLCas of 30 Sep 2023 | 27.74k | 0.01% |
